UB Center for Clinical Ethics and Humanities in
Health Care

Clinical Pharmacology Conference

Jeffrey Kahn, PhD, MPH
Director
Center for Bioethics
University of Minnesota

PAST AND PRESENT LESSONS IN THE ETHICS OF CLINICAL RESEARCH

Friday October 24, 1997
9:30AM, Webster Hall
Millard Fillmore Gates Circle

The ethics of clinical research are longstanding. These issues have been discussed since long before the advent of federal regulations, and continue to test our sense of morally acceptable research. This presentation will discuss some of these issues in light of some recent findings. Many of these issues will be familiar, but I hope to offer some new insights into their origins approaches to their resolution.

I will focus on five overlapping and recurring issues: quality of informed consent, confusion between research and therapy, therapeutic misconception, blurring roles and potential for conflict of interest in some cases of physicians who are also investigators, and overarching trust by subjects in researchers, institutions and the research process.

New research on all of these issues from both a historical and contemporary perspective comes from the literature and recent federal efforts. Some examples:

  1. Interviews with researchers active during the Cold War indicated that consent was not obtained from sick hospitalized patients in research even though consent was obtained from healthy subjects. The first formal policy requiring written informed consent was implemented at the NIH Clinical Center in 1966.
  2. The US Department of Defense (DoD) had a policy requiring informed consent and other safeguards for research subjects in DoD-sponsored research as early as 1953, but it was largely ignored. In fact, part of the problem may have been that this policy was classified Top Secret.
  3. A 1995 study of 125 IRB-approved and government funded research protocols found that 14% of the proposals raised significant ethical concerns. When only greater than minimal risk studies are considered, almost 30 percent of the proposals reviewed raised significant ethical concerns.
  4. Research subjects misinterpret the risk and benefit of research participation, engaging in what has come to be called the "therapeutic misconception." A 1994 study showed that even in Phase I trials, the vast majority of subjects and a majority of referring physicians surveyed stated that they believed research would benefit subjects.
  5. A 1995 study showed that some proportion (less than 10%) of research subjects believe they are not in research but are receiving therapy. Conversely, a similar proportion of patients who are not in research believe that they are. This points out the confusion between research and therapy on the part of patient-subjects.
In spite of the above and other examples, research subjects still have overarching trust in research and those who carry it out. They trust researchers and the physicians who recommend participation; they trust hospitals, in which research is carried out; and they trust the system of rules and regulations, which protects their rights and interests.

This presentation will examine some of the historical and current evidence and analysis around the five issues noted, and will conclude with what the future holds in terms of the ethics of clinical research.

Co-sponsored by the UB Department of Medicine, Divison of Clinical Pharmacology, and Millard Fillmore Clinical Pharmacokinetics Lab.


Return to Bioethics Events Page.